Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Leuprorelin dual chamber syringe

The manufacturer of leuprorelin (Prostap®) injections has written to healthcare professionals advising that the current presentation will be replaced with effect from the 4th of July 2011 and with a dual chamber syringe (DCS) system.

The one month (Prostap SR) and three month (Prostap 3) presentations are both affected by this change with the product license and price remaining unchanged. The manufacturer reports that the DCS system is simple to use and that the existing products will be discontinued in October 2011.

Action: Clinicians should be aware of this product presentation change. Clinicians who use Prostap products should ensure that usage instructions for the new product are followed.

Share 'Leuprorelin dual chamber syringe' on Email Share 'Leuprorelin dual chamber syringe' on Delicious Share 'Leuprorelin dual chamber syringe' on Digg Share 'Leuprorelin dual chamber syringe' on Facebook Share 'Leuprorelin dual chamber syringe' on Google+ Share 'Leuprorelin dual chamber syringe' on reddit Share 'Leuprorelin dual chamber syringe' on StumbleUpon Share 'Leuprorelin dual chamber syringe' on Twitter

atomic-wealth

No Comments to “Leuprorelin dual chamber syringe”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,208 spam comments.

atomic-wealth
fond-illness
summer